BackIntellia Therapeutics Overview

Intellia Therapeutics Receivables

Latest receivables for NTLA: $9.1M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$9.13M
13.07% YoYΔ $-1.37M vs prior year quarter

Peer average

Loading

Intellia Therapeutics Receivables History

Loading

Intellia Therapeutics vs. peers: Receivables Comparison

Loading

Intellia Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Intellia Therapeutics (NTLA) FAQ

As of the most recent data (March 2026), NTLA shows a receivables of $9.1M. That compares with $11M in the prior-year period — down 13.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NTLA's receivables is now $9.1M (was $11M) — a 13.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Intellia Therapeutics is outperforming or lagging.

Tracking NTLA's receivables over time shows whether Intellia Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $9.1M That compares with $11M in the prior-year period — down 13.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Intellia Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $9.1M) with ownership activity and broader fundamentals.

Intellia Therapeutics's receivables is $9.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.